US7148359B2ExpiredUtilityPatentIndex 92

Polymorph of a pharmaceutical

Assignee: ABBOTT LABPriority: Jul 20, 1998Filed: May 4, 2005Granted: Dec 12, 2006

Est. expiryJul 20, 2018(expired)· nominal 20-yr term from priority

Inventors:CHEMBURKAR SANJAY R PATEL KETAN

C07D 277/28C07D 417/12A61P 31/18

PatentIndex Score

Cited by

References

Claims

Abstract

A new crystalline polymorph of ritonavir and methods for its use and preparation are disclosed.

Claims

exact text as granted — not AI-modified

1. Substantially pure amorphous ritonavir. 
     
     
       2. The substantially pure amorphous ritonavir of  claim 1  characterized by a glass transition from about 45° C. to about 49° C. 
     
     
       3. A composition comprising amorphous ritonavir. 
     
     
       4. The composition of  claim 3 , wherein said amorphous ritonavir is substantially pure. 
     
     
       5. The composition of  claim 3 , wherein greater than about 90% of ritonavir in said composition is amorphous ritonavir. 
     
     
       6. The composition of  claim 3 , wherein greater than about 95% of ritonavir in said composition is amorphous ritonavir. 
     
     
       7. The composition of  claim 3 , wherein greater than about 97% of ritonavir in said composition is amorphous ritonavir.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.